Ceribell, Inc. CBLL 深 沪
已收盘 02-06 16:00:00 美东时间
20.15
+0.810
+4.19%
华盛通- 最 高20.27
- 今 开19.40
- 成交量 50.32万股
- 最 低 18.78
- 昨 收 19.34
- 总市值 7.47亿
- 52周最高 26.04
- 市盈率 静 --
- 换手率 1.36%
- 52周最低 10.01
- 委 比 8.79%
- 总股本 3709.57万
- 历史最高 32.7489
- 量 比 1.45
- 振 幅 7.70%
- 历史最低 10.01
- 每 手 1
- 风险率 3.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
BTIG Reiterates Buy on CeriBell, Maintains $30 Price Target
BTIG analyst Marie Thibault reiterates CeriBell (NASDAQ:CBLL) with a Buy and maintains $30 price target.
01-28 21:32
Analysts’ Top Healthcare Picks: Ceribell, Inc. (CBLL), Evommune, Inc. (EVMN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
01-06 01:50
Protara, CeriBell rise on FDA breakthrough designations
Protara Therapeutics (TARA) and CeriBell (CBLL) were among the notable healthcare gainers on Monday after the FDA issued breakthrough designations for their experimental products, TARA-002 cell-based ...
01-06 00:00
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Ceribell, Inc. has received FDA Breakthrough Device Designation for its AI-based LVO stroke detection monitor, which uses EEG signals to enable early detection of large vessel occlusion strokes in hospitalized patients. This technology aims to address delays in stroke detection and treatment, improving outcomes for vulnerable patients.
01-05 13:00
Ceribell director resigns to pursue other professional ventures
The latest announcement is out from Ceribell, Inc. ( ($CBLL) ). On December 30,...
01-03 06:20
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Ceribell, Inc. announced that Jane Chao, CEO and Co-founder, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:00 am PST / 12:00 pm EST in San Francisco. The presentation will be available live and archived on the company's Investor Relations page. Ceribell, a medical technology company, has developed the FDA-cleared Ceribell System, a portable EEG platform designed for rapid diagnosis and monitoring of n...
2025-12-30 21:05
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
BTIG Reiterates Buy on CeriBell, Maintains $30 Price Target
BTIG analyst Marie Thibault reiterates CeriBell (NASDAQ:CBLL) with a Buy and maintains $30 price target.
2025-12-15 18:39
